Mainz Biomed BV
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes … Read more
Mainz Biomed BV (MYNZ) - Total Assets
Latest total assets as of June 2025: $9.80 Million USD
Based on the latest financial reports, Mainz Biomed BV (MYNZ) holds total assets worth $9.80 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mainz Biomed BV - Total Assets Trend (2019–2024)
This chart illustrates how Mainz Biomed BV’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mainz Biomed BV - Asset Composition Analysis
Current Asset Composition (December 2024)
Mainz Biomed BV's total assets of $9.80 Million consist of 59.3% current assets and 40.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.1% |
| Accounts Receivable | $213.75K | 1.6% |
| Inventory | $372.87K | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.02 Million | 22.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Mainz Biomed BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mainz Biomed BV's current assets represent 59.3% of total assets in 2024, an increase from 36.3% in 2019.
- Cash Position: Cash and equivalents constituted 47.1% of total assets in 2024, up from 28.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 22.8% of total assets.
Mainz Biomed BV Competitors by Total Assets
Key competitors of Mainz Biomed BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Mainz Biomed BV - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mainz Biomed BV generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mainz Biomed BV is currently not profitable relative to its asset base.
Mainz Biomed BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 0.24 | 0.27 |
| Quick Ratio | 0.43 | 0.19 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.90 Million | $ -7.62 Million | $ -128.89K |
Mainz Biomed BV - Advanced Valuation Insights
This section examines the relationship between Mainz Biomed BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.87 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -14.1% |
| Total Assets | $13.24 Million |
| Market Capitalization | $2.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mainz Biomed BV's assets below their book value (0.20 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mainz Biomed BV's assets decreased by 14.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mainz Biomed BV (2019–2024)
The table below shows the annual total assets of Mainz Biomed BV from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $13.24 Million | -14.09% |
| 2023-12-31 | $15.41 Million | -23.87% |
| 2022-12-31 | $20.24 Million | +101.59% |
| 2021-12-31 | $10.04 Million | +1391.35% |
| 2020-12-31 | $673.27K | -5.96% |
| 2019-12-31 | $715.96K | -- |